AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer.

AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer.

Item
http://www.wikidata.org/entity/Q37826430
Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors.Suppression of KSHV-induced angiopoietin-2 inhibits angiogenesis, infiltration of inflammatory cells, and tumor growth.Translation of molecular pathways into clinical trials of neuroendocrine tumors.Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment.Targeting angiogenesis in renal cell carcinoma.Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.Fcγ1 fragment of IgG1 as a powerful affinity tag in recombinant Fc-fusion proteins: immunological, biochemical and therapeutic properties.Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis.Peptibodies: An elegant solution for a long-standing problem.Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.Computational Design of Antiangiogenic Peptibody by Fusing Human IgG1 Fc Fragment and HRH Peptide: Structural Modeling, Energetic Analysis, and Dynamics Simulation of Its Binding Potency to VEGF Receptor.
P2860

AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer.

Item
http://www.wikidata.org/entity/Q37826430
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer.
@en
AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer.
@nl
type
label
AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer.
@en
AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer.
@nl
prefLabel
AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer.
@en
AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P356
P1433
P1476
AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer.
@en
P2093
P2860
P304
P31
P356
10.1517/13543784.2011.549125
P407
P433
P478
P577
P698
P921